Treatment discontinuation rates due to lack of efficacy through 1 year of maintenance treatment with vedolizumab or subcutaneous infliximab in patients with inflammatory bowel disease: a systematic literature review and meta-analysis. - Ferrante, Marc; Peyrin-Biroulet, Laurent; Arkkila, Perttu; Armuzzi, Alessandro; Colombel, Jean-Frédéric; Danese, Silvio; Faggiani, Roberto; Guardiola, Jordi; Hanauer, Stephen B.; Jahnsen, Jorgen; Reinisch, Walter; Roblin, Xavier; et al. (Therapeutic Advances in Gastroenterology, 2025)